Tandem Capital Management Corp ADV Sells 6,946 Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART)

Tandem Capital Management Corp ADV lessened its holdings in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) by 25.6% in the third quarter, according to its most recent filing with the SEC. The firm owned 20,140 shares of the life sciences company’s stock after selling 6,946 shares during the period. Tandem Capital Management Corp ADV’s holdings in Integra LifeSciences were worth $366,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Capital Research Global Investors lifted its stake in shares of Integra LifeSciences by 37.7% in the 1st quarter. Capital Research Global Investors now owns 5,918,981 shares of the life sciences company’s stock valued at $209,828,000 after purchasing an additional 1,621,655 shares during the period. Cooke & Bieler LP lifted its stake in shares of Integra LifeSciences by 12.4% in the 2nd quarter. Cooke & Bieler LP now owns 3,514,281 shares of the life sciences company’s stock valued at $102,406,000 after purchasing an additional 388,710 shares during the period. Champlain Investment Partners LLC lifted its stake in shares of Integra LifeSciences by 10.3% in the 1st quarter. Champlain Investment Partners LLC now owns 2,687,972 shares of the life sciences company’s stock valued at $95,289,000 after purchasing an additional 252,015 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of Integra LifeSciences by 0.7% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,785,009 shares of the life sciences company’s stock valued at $52,014,000 after purchasing an additional 12,766 shares during the period. Finally, D. E. Shaw & Co. Inc. lifted its stake in shares of Integra LifeSciences by 64.6% in the 2nd quarter. D. E. Shaw & Co. Inc. now owns 855,352 shares of the life sciences company’s stock valued at $24,925,000 after purchasing an additional 335,557 shares during the period. Institutional investors own 84.78% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the stock. Truist Financial lowered their price objective on shares of Integra LifeSciences from $26.00 to $21.00 and set a “hold” rating for the company in a research report on Monday, October 14th. JMP Securities lowered their price objective on shares of Integra LifeSciences from $40.00 to $35.00 and set a “market outperform” rating for the company in a research report on Tuesday, July 30th. Bank of America lowered their price objective on shares of Integra LifeSciences from $26.00 to $18.00 and set an “underperform” rating for the company in a research report on Monday, October 7th. BTIG Research upgraded shares of Integra LifeSciences from a “sell” rating to a “neutral” rating in a research report on Monday, October 7th. Finally, Morgan Stanley upped their price objective on shares of Integra LifeSciences from $24.00 to $27.00 and gave the company an “underweight” rating in a research report on Monday, July 15th. Three analysts have rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the company. According to MarketBeat.com, Integra LifeSciences presently has an average rating of “Hold” and an average price target of $26.50.

Integra LifeSciences Price Performance

Shares of NASDAQ IART opened at $19.48 on Thursday. The stock has a market capitalization of $1.51 billion, a price-to-earnings ratio of 67.17, a PEG ratio of 0.65 and a beta of 1.09. The business has a 50-day moving average of $18.69 and a 200-day moving average of $24.70. The company has a debt-to-equity ratio of 1.17, a current ratio of 3.39 and a quick ratio of 2.10. Integra LifeSciences Holdings Co. has a fifty-two week low of $16.81 and a fifty-two week high of $45.42.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings data on Monday, July 29th. The life sciences company reported $0.63 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.01. The company had revenue of $418.20 million during the quarter, compared to analysts’ expectations of $413.07 million. Integra LifeSciences had a return on equity of 14.07% and a net margin of 1.51%. Integra LifeSciences’s revenue for the quarter was up 9.7% compared to the same quarter last year. During the same quarter last year, the company earned $0.71 EPS. As a group, sell-side analysts predict that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current fiscal year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.